<DOC>
	<DOCNO>NCT02883036</DOCNO>
	<brief_summary>Chronic myeloid leukemia ( CML ) myeloproliferative neoplasm company BCR-ABL fusion gene encode Philadelphia ( Ph ) chromosome . The BCR-ABL fusion protein ( formation chimeric gene BCR/ABL chromosome 22 reciprocal ABL/BCR chromosome 9 , expand name ) play key role CML leukemogenesis activate downstream signal pathway survival proliferation . Imatinib , target competitive inhibitor BCR-ABL tyrosine kinase , change clinical treatment prognosis CML . As optimized generation , tyrosine kinase inhibitor ( TKIs ) , dasatinib nilotinib potent anti-leukemic activity less side-effect . However , acquire resistance TKIs one main obstacle effective CML treatment involve gene amplication ABL tyrosine kinase point mutation . The outcomes patient ABL tyrosine kinase point mutation link bad prognosis high mortality generally . Metabolic adaptation common cancer cell , cancer cell become dependent mitochondrial biogenesis . Tigecycline , broad-spectrum antibiotic , inhibits mitochondrial biogenesis interest `` side-effect '' .In recent study , researcher indicate tigecycline eradicate cancer stem cell target mitochondrial.Here , investigator test tigecycline 's anti-leukemic activity chronic myeloid leukemia vitro .</brief_summary>
	<brief_title>Vitro Study Tigecycline Treat Chronic Myeloid Leukemia</brief_title>
	<detailed_description>In study , investigator collect bone marrow ( BM ) or/and peripheral blood ( PB ) mononuclear cell patient chronic myeloid leukemia.Patients could different stage chronic myeloid leukemia pre-treatment.Additionally , investigator also select healthy volunteer comparison.Firstly , investigator analyze mitochondrial biogenesis basal metabolic characteristic mononuclear cell patient healthy volunteers.Secondly , investigator test cell viability apoptosis tigecycline treatment.Thirdly , investigator detect change cell mitochondrial biogenesis metabolic characteristic study sample tigecycline stimulation . Finally , investigator analyze correlation sensitivity mononuclear cell tigecycline patient ' clinical parameter survival outcome .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Diagnosis Philadelphia chromosome positive and/or BCRABL positive CML confirm cytogenetic and/or molecular analysis ; Age &gt; 18 year . Eligibility patient receive medication substance know affect determine follow review case Principal Investigator Patients may receive antibiotic . Patients may receive prior treatment TKIs hydroxyurea . Major cognitive deficit psychiatric problem hamper selfreported evaluation . No prior malignancy cancer patient disease free 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>tigecycline</keyword>
	<keyword>treatment</keyword>
	<keyword>mitochondrial biogenesis</keyword>
	<keyword>metabolic characteristic</keyword>
</DOC>